Impact of etanercept tapering on work productivity in patients with early rheumatoid arthritis: results from the PRIZE study

Wei Zhang, Nick Bansback, Huiying Sun, Ronald Pedersen, Sameer Kotak, Aslam H Anis, Wei Zhang, Nick Bansback, Huiying Sun, Ronald Pedersen, Sameer Kotak, Aslam H Anis

Abstract

Objective: To assess changes in work productivity in patients who have achieved response using etanercept (ETN) 50 mg+methotrexate (MTX) (phase I) are randomised to ETN 25 mg+MTX versus MTX versus placebo (phase II) and then withdrawn from treatment (phase III).

Methods: Patients included in the analysis were in employment entering phase II of the PRIZE trial and had one or more follow-ups. Phase II was a 39-week, randomised and double-blind comparison of the 3 dose-reduction treatments. Phase III was a 26-week observational study where treatment was withdrawn. The Valuation of Lost Productivity was completed approximately every 13 weeks to estimate productivity impacts from a societal perspective.

Results: A total of 120 participants were included in our analyses. During phase II, ETN25+MTX or MTX improved paid work productivity by over 100 hours compared with placebo, amounting to a gain of €1752 or €1503, respectively. ETN25+MTX compared with placebo gains €1862 in total paid/unpaid productivity. At week 52, the 3-month paid work productivity loss was 21.8, 12.8 and 14.0 hours, respectively. The productivity loss increased at week 64 from week 52, dropped at week 76 for all treatment groups and then continued rising after week 76 for the placebo group (71.9 hours at week 91) but not for the other 2 groups (21.9 hours for ETX25+MTX and 27.6 hours for MTX).

Conclusions: The work productivity gain in phase I as a result of ETN50+MTX was marginally lost in the dose-reduction treatment groups, ETN25+MTX and MTX, but substantially lost in the placebo group during phase II.

Trial registration number: NCT00913458; Results.

Keywords: Arthritis; Early Rheumatoid Arthritis; Economic Evaluations; Rheumatoid Arthritis.

Figures

Figure 1
Figure 1
Study design. ETN50+MTX, etanercept 50 mg plus methotrexate; ETN25+MTX, etanercept 25 mg plus methotrexate; MTX, methotrexate.
Figure 2
Figure 2
Plots of 3-month paid productivity loss in hours at each visit during the entire study period. E50+MTX, etanercept 50 mg plus methotrexate; E25+MTX, etanercept 25 mg plus methotrexate; MTX, methotrexate.

References

    1. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006;54:2784–92. 10.1002/art.22052
    1. Mäkinen H, Kautiainen H, Hannonen P et al. . Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol 2007;34:316–21.
    1. Rantalaiho V, Korpela M, Hannonen P et al. . The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum 2009;60:1222–31. 10.1002/art.24447
    1. Puolakka K, Kautiainen H, Möttönen T et al. . Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005;52:36–41. 10.1002/art.20716
    1. Puolakka K, Kautiainen H, Möttönen T et al. . Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum 2004;50:55–62. 10.1002/art.11436
    1. Anis A, Zhang W, Emery P et al. . The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Rheumatology (Oxford) 2009;48:1283–9. 10.1093/rheumatology/kep239
    1. Verstappen SMM, Fautrel B, Dadoun S et al. . Methodological issues when measuring paid productivity loss in patients with arthritis using biologic therapies: an overview of the literature. Rheumatology (Oxford) 2012;51:216–29. 10.1093/rheumatology/ker363
    1. Zhang W, Bansback N, Anis AH. Measuring and valuing productivity loss due to poor health: a critical review. Soc Sci Med 2011;72:185–92. 10.1016/j.socscimed.2010.10.026
    1. Zhang W, Bansback N, Boonen A et al. . Development of a composite questionnaire, the valuation of lost productivity, to value productivity losses: application in rheumatoid arthritis. Value Health 2012;15:46–54. 10.1016/j.jval.2011.07.009
    1. Emery P, Hammoudeh M, FitzGerald O et al. . Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med 2014;371:1781–92. 10.1056/NEJMoa1316133
    1. Zhang W, Bansback N, Sun H et al. . Estimating the monetary value of the annual productivity gained in patients with early rheumatoid arthritis receiving etanercept plus methotrexate: interim results from the PRIZE study. RMD Open 2015;1:e000042 10.1136/rmdopen-2014-000042
    1. Zhang W, Bansback N, Kopec J et al. . Measuring time input loss among patients with rheumatoid arthritis: validity and reliability of the Valuation of Lost Productivity questionnaire. J Occup Environ Med 2011;53:530–6. 10.1097/JOM.0b013e318218abf1
    1. World Bank. PPP conversion factor. (accessed 2 Oct 2014).
    1. Eurostat. Mean hourly earnings by sex, economic activity and occupation (earn_ses10_47). (accessed 12 Sep 2014).
    1. Westfall PH. Resampling-based multiple testing: examples and methods for P-value adjustment. New York: Wiley, 1993.
    1. Westfall PH. On using the bootstrap for multiple comparisons. J Biopharm Stat 2011;21:1187–205. 10.1080/10543406.2011.607751
    1. Greene WH. W. H. Greene's 6th(sixth) edition (Econometric Analysis [Hardcover]). 6th edn. Prentice Hall, 2007.
    1. Manly BFJ. Randomization, bootstrap and Monte Carlo methods in biology. 3rd edn Boca Raton: (FL: ): Chapman and Hall/CRC, 2006.
    1. MacKINNON JG. Bootstrap methods in econometrics. Econ Rec 2006;82:S2–18. 10.1111/j.1475-4932.2006.00328.x
    1. Efron B, Tibshirani RJ. An introduction to the bootstrap. CRC Press, 1994.
    1. Lenssinck ML, Burdorf A, Boonen A et al. . Consequences of inflammatory arthritis for workplace productivity loss and sick leave: a systematic review. Ann Rheum Dis 2013;72:493–505. 10.1136/annrheumdis-2012-201998
    1. Koopmanschap MA, Rutten FF, van Ineveld BM et al. . The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:171–89. 10.1016/0167-6296(94)00044-5
    1. Jacob-Tacken KH, Koopmanschap MA, Meerding WJ et al. . Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes. Health Econ 2005;14:435–43. 10.1002/hec.948
    1. Krol M, Brouwer WBF, Severens JL et al. . Productivity cost calculations in health economic evaluations: correcting for compensation mechanisms and multiplier effects. Soc Sci Med 2012;75:1981–8. 10.1016/j.socscimed.2012.07.012
    1. Johannesson M, Karlsson G. The friction cost method: a comment. J Health Econ 1997;16:249–55; discussion 257–9. 10.1016/S0167-6296(97)00006-4
    1. Koopmanschap MA, Rutten FFH, van Ineveld BM et al. . Reply to Johanneson's and Karlsson's comment. J Health Econ 1997;16:257–9. 10.1016/S0167-6296(96)00524-3

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe